Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Jenq, Robert R ^a,b   Curran, Michael A ^a   Goldberg, Gabrielle L ^a   Liu, Chen ^c   Allison, James P ^a   van den Brink, Marcel R M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; DDX3Y PROTEIN, MOUSE; DEAD BOX PROTEIN; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ALLOGENEIC RESTRICTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CONTROL; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE TRANSFER; MALE; MOUSE; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PROSTATE ADENOCARCINOMA; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; Y CHROMOSOME; ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; ADULT; ANIMAL; CANCER TRANSPLANTATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE COUNT; METHODOLOGY; PROSTATE TUMOR; SEX DIFFERENCE; TRANSPLANTATION; WHOLE BODY RADIATION;

ANIMALIA; MURINAE; MUS;

ADENOCARCINOMA; ADULT; ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEAD-BOX RNA HELICASES; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE COUNT; MALE; MICE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SEX FACTORS; WHOLE-BODY IRRADIATION;

EID: 84859498754     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035222     Document Type: Article

References (31)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
2. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, et al. (2009) Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106: 2729-2734.
3. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, et al. (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69: 609-615.
4. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, et al. (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A 108: 17087-17092.
5. Xu LL, Su YP, Labiche R, Segawa T, Shanmugam N, et al. (2001) Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 92: 322-328.
6. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, et al. (1998) Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58: 5718-5724.
7. Dasari VK, Goharderakhshan RZ, Perinchery G, Li LC, Tanaka Y, et al. (2001) Expression analysis of Y chromosome genes in human prostate cancer. J Urol 165: 1335-1341.
8. Barrett AJ, (2008) Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 142: 877-888.
9. Kolb HJ, (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112: 4371-4383.
10. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, et al. (2001) Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98: 2043-2051.
11. Flowers ME, Pepe MS, Longton G, Doney KC, Monroe D, et al. (1990) Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol 74: 492-496.
12. Atkinson K, Farrell C, Chapman G, Downs K, Penny R, et al. (1986) Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 63: 231-239.
13. Turcotte S, Rosenberg SA, (2011) Immunotherapy for metastatic solid cancers. Adv Surg 45: 341-360.
14. Sykes M, Sharabi Y, Sachs DH, (1988) Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant 3: 379-386.
15. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, et al. (2002) Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100: 1903-1909.
16. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED, (2001) The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol Chapter 20: Unit 20 25.
17. Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, et al. (2008) SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A 105: 3509-3514.
18. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, et al. (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57: 4687-4691.
19. Curran MA, Allison JP, (2009) Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 69: 7747-7755.
20. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM, (2007) In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 67: 1344-1351.
21. Yi H, Yu X, Guo C, Manjili MH, Repasky EA, et al. (2011) Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. Cancer Immunol Immunother 60: 349-360.
22. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, et al. (2007) CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354.
23. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
24. Peggs KS, Quezada SA, Allison JP, (2008) Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 224: 141-165.
25. Yanagisawa S, Koike M, Kariyone A, Nagai S, Takatsu K, (1997) Mapping of V beta 11+ helper T cell epitopes on mycobacterial antigen in mouse primed with Mycobacterium tuberculosis. Int Immunol 9: 227-237.
26. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM, (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325-3330.
27. Na IK, Lu SX, Yim NL, Goldberg GL, Tsai J, et al. (2010) The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest 120: 343-356.
28. Jenq RR, King CG, Volk C, Suh D, Smith OM, et al. (2009) Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood 113: 1574-1580.
29. Curran MA, Montalvo W, Yagita H, Allison JP, (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107: 4275-4280.
30. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, et al. (1996) An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88: 3230-3239.
31. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, et al. (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90: 3204-3213.